Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Competition Intensifies on Market for Antidepressants
April 29, 2002
-
ARCHIVE Companies' Responsibility for Promotion of Medical Safety Clarified
April 29, 2002
-
ARCHIVE We Are Open to Strategic Alliance: Mr Wright of AstraZeneca
April 29, 2002
-
ARCHIVE Eisai to Apply for Vascular Dementia for Aricept in US
April 29, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
April 29, 2002
-
ARCHIVE Mr Nordhoff Talks about Prospects of Gen-Probe
April 29, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 29, 2002
-
ARCHIVE PhRMA Japan Representative Discusses AIDS in Developing Countries
April 29, 2002
-
ARCHIVE BI to Introduce Int'l Strategic Products into Japan
April 29, 2002
-
ARCHIVE Aventis, Fujisawa Form Alliance for Marketing of Synercid Injection
April 29, 2002
-
ARCHIVE Korosho to Beef Up Measures to Ensure Medical Safety
April 29, 2002
-
ARCHIVE SSP Licenses Spelear to Han All Pharm in South Korea
April 29, 2002
-
ARCHIVE Medical Facilities Run by Profit-making Firms to Be Discussed Again
April 29, 2002
-
ARCHIVE Vital-Net, Ohmori Yakuhin Tohoku to Merge in July
April 29, 2002
-
ARCHIVE Tokai Univ. Initiates Drug Discovery Project
April 29, 2002
-
ARCHIVE Animal Study Contracts Increasing: Huntingdon Life Sciences
April 29, 2002
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 29, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
April 29, 2002
-
ARCHIVE Tokyo Katei Yakko Proposes New Distribution for Home Remedies
April 29, 2002
-
ARCHIVE WEBSITE NEWS
April 29, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…